- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07598734
Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty
Doxepin Versus Doxepin and Ramelteon Versus Placebo to Improve Sleep Quality After Primary Total Knee Arthroplasty: A Randomized Controlled Trial
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Gerald Y Liao, MS
- Número de telefone: 617-710-7211
- E-mail: liaog@uw.edu
Estude backup de contato
- Nome: Nicholas M Hernandez, MD
- Número de telefone: 530-514-1275
- E-mail: nichern@uw.edu
Locais de estudo
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98133
- University of Washington Medical Center Hip & Knee Center
-
Contato:
- Portia Morgan
- Número de telefone: 206-668-3674
- E-mail: morganp9@uw.edu
-
Investigador principal:
- Nicholas M Hernandez, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Those receiving primary total knee arthroplasty (TKA)
- 80 years or less, age 18 or greater
Exclusion Criteria:
- History of cardiovascular bundle branch block
- Actively taking selecrtive serotoin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or having treatment via counseling/psychotherapy for major depression or anxiety, bipolar, or psychotic disorder
- Pre-operative narcotics (defined as more than 1 prescription in the past 3 months)
- Self-reported use of alcohol in excess of >2 drinks/day (in men) and > 1 drink/day (in women)
- Use of prescription sleep aids (e.g., Ambien, Trazadone) prior to surgery (i.e., melatonin or other OTC sleep aids are permitted)
- History of major sleep disorder (e.g., obstructive sleep apnea (OSA), restless leg syndrome, narcolepsy)
- Pregnant, breastfeeding or planning to become pregnant in the next 3 months post-surgery. No pregnancy testing will be performed; screening will rely solely on participant self-report.
- Unable to take the study medication(s) due to contraindications with other medications the patient uses
- Have been diagnosed with (or are at risk of) narrow-angle or angle-closure glaucoma. In order to be eligible, participants must be able to report that they have had their eyes dilated within the past year without problems.
- Have severe urinary retention or difficulty emptying your bladder.
- Had glaucoma-related eye procedures (e.g., laser iridotomy)
- Ongoing use of glaucoma eye drops.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Doxepin 6 mg
Participants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Experimental: Doxepin 6 mg and Ramelteon 8mg
Participants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Ramelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Comparador de Placebo: Placebo
Participants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Placebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Insomnia Severity Index (ISI) scores (sleep quality)
Prazo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Insomnia Severity Index (ISI) The Insomnia Severity Index is a 7-item self-reported questionnaire assessing the nature, severity, and impact of insomnia.
Score categories:
|
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS)
Prazo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS): The KOOS-PS is a 7-item patient-reported outcome measure assessing knee-related physical function, including activities such as rising from bed, putting on socks, rising from sitting, bending to the floor, twisting/pivoting, kneeling, and squatting . Each item is scored on a 5-point Likert scale (None to Extreme). Scores are transformed to a normalized scale ranging from 0 to 100, with higher scores indicating worse physical function (greater disability). |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR)
Prazo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR): The KOOS-JR is a patient-reported outcome measure assessing knee pain, stiffness, and functional limitations during activities of daily living over the past week, including tasks such as twisting/pivoting, stair navigation, standing, rising from sitting, and bending . The instrument consists of 7 items scored on a 5-point Likert scale (None to Extreme). Raw scores (range 0-28) are summed and converted to an interval score ranging from 0 to 100, where 0 represents total knee disability and 100 represents perfect knee health (higher scores indicate better outcomes) |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10)
Prazo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10): The PROMIS-10 is a 10-item patient-reported outcome measure assessing global physical health, mental health, pain, fatigue, and social functioning. Items are scored on 5-point Likert scales (e.g., Excellent to Poor; Not at all to Very much), with one pain item scored from 0 to 10. Raw scores are summed and converted to standardized T-scores for Global Physical Health and Global Mental Health, each ranging approximately from 0 to 100 (mean 50, standard deviation 10), where higher scores indicate better health status |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
90-Day Hospital Readmission Status
Prazo: Within 90 days postoperatively
|
Hospital readmission status within 90 days following primary total knee arthroplasty, defined as any unplanned inpatient admission to a hospital occurring within 90 days after the index procedure.
This is a dichotomous outcome (Yes/No), where "Yes" indicates that a readmission occurred and represents a worse outcome.
|
Within 90 days postoperatively
|
|
Medication Compliance
Prazo: 2 weeks postoperatively; 6 weeks postoperatively
|
Medication Compliance: Medication adherence assessed using patient self-report and pill counts when feasible. Self-reported adherence is measured by patient-reported proportion of prescribed doses taken, and pill counts are used to calculate the percentage of medication consumed relative to the prescribed amount. Adherence is expressed as a percentage from 0 to 100%, where higher values indicate better compliance. |
2 weeks postoperatively; 6 weeks postoperatively
|
|
Length of Stay (LOS)
Prazo: Perioperative/Periprocedural
|
Length of Stay (LOS): Length of hospital stay following primary total knee arthroplasty, defined as the number of days from hospital admission to discharge (continuous variable, ≥0 days), where higher values indicate longer hospitalization (worse outcome). |
Perioperative/Periprocedural
|
|
Discharge Destination
Prazo: Perioperative/Periprocedural
|
Discharge Destination: Discharge disposition following primary total knee arthroplasty, categorized as home versus skilled nursing facility. This is a categorical outcome where discharge to a skilled nursing facility represents a worse outcome compared to discharge home. |
Perioperative/Periprocedural
|
|
Postoperative Mobility (Step Count)
Prazo: Perioperative/Periprocedural
|
Postoperative Mobility (Step Count): Postoperative mobility assessed by the number of steps taken during inpatient physical therapy sessions following primary total knee arthroplasty. Step count is recorded as the total number of steps ambulated (continuous variable, ≥0), where higher values indicate better functional recovery. |
Perioperative/Periprocedural
|
|
Level of Assistance Required for Ambulation
Prazo: Perioperative/Periprocedural
|
Level of Assistance Required for Ambulation: Level of assistance required during inpatient physical therapy following primary total knee arthroplasty, categorized as independent, 1-person assist, 2-person assist, or maximal assist. This is an ordinal outcome where greater assistance requirements indicate worse functional recovery. |
Perioperative/Periprocedural
|
|
Postoperative Falls
Prazo: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Falls: Occurrence of patient falls during hospitalization or within the follow-up period after primary total knee arthroplasty, defined as any unintentional descent to the ground or lower level documented in the medical record.
This is a dichotomous outcome (Yes/No), where "Yes" indicates a fall occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Delirium
Prazo: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of delirium during hospitalization or follow-up after primary total knee arthroplasty, defined by clinical documentation of acute confusional state or use of delirium-related precautions (e.g., 1:1 sitter, physical restraints).
This is a dichotomous outcome (Yes/No), where "Yes" indicates delirium occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Pressure Ulcers (Bed Sores)
Prazo: Perioperative/Periprocedural; 3 months postoperatively
|
Pressure Ulcers (Bed Sores): Development of pressure ulcers during hospitalization or follow-up after primary total knee arthroplasty, defined as localized injury to the skin or underlying tissue documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a pressure ulcer occurred and represents a worse outcome. |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents)
Prazo: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents): Total postoperative opioid use following primary total knee arthroplasty, calculated as cumulative morphine milligram equivalents (MME) administered during hospitalization and follow-up. This is a continuous variable (≥0 mg), where higher values indicate greater opioid consumption (worse outcome). |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Medical Complications
Prazo: Perioperative/Periprocedural
|
Postoperative Medical Complications: Occurrence of medical complications following primary total knee arthroplasty, including myocardial infarction, venous thromboembolism, cerebrovascular accident, acute kidney injury, respiratory failure, urinary tract infection, pneumonia, gastrointestinal obstruction, and need for intensive care unit (ICU) admission during the same hospitalization. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome. |
Perioperative/Periprocedural
|
|
Postoperative Surgical Complications
Prazo: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of surgical complications following primary total knee arthroplasty, including reoperation, periprosthetic fracture, dislocation, infection, and postoperative stiffness.
This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Nicholas M Hernandez, MD, University of Washington
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- STUDY00024373
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .